IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsubota, K.
Right arrow Articles by Hayashi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsubota, K.
Right arrow Articles by Hayashi, Y.
(Investigative Ophthalmology and Visual Science. 2001;42:101-110.)
© 2001 by The Association for Research in Vision and Ophthalmology, Inc.

Improvement of Lacrimal Function by Topical Application of CyA in Murine Models of Sjögren’s Syndrome

Kazuo Tsubota1,2, Hiromi Fujita1, Kimie Tadano1, Tsutomu Takeuchi3, Tadahiro Murakami4, Ichiro Saito4 and Yoshio Hayashi4

1 From the Department of Ophthalmology and Oral Health Science Center, Tokyo Dental College, Chiba; the 2 Department of Ophthalmology, Keio University School of Medicine, Tokyo; the 3 Second Department of Internal Medicine, Saitama Medical Center, Saitama; and the 4 Department of Pathology, Tokushima University School of Dentistry, Tokushima, Japan.

PURPOSE. The object of this study was to evaluate improvement of lacrimal gland (LG) function after topical cyclosporin A (CyA).

METHODS. Topical CyA (0.01% and 0.1%) was applied to two mouse models of Sjögren’s syndrome, the NFS/sld after thymectomy and the nonobese diabetic (NOD) mouse, and the functional integrity of the lacrimal gland was evaluated by measuring basal and stimulated tear secretion and its histologic integrity by examining it for apoptosis and lymphocyte invasion.

RESULTS. After treatment with CyA at 0.1% in the NFS/sld mice, tear function increased, and there was a decrease in lymphocyte infiltration of the LG and a decrease in apoptotic figures among the acinar cells. In the NOD mice, tear function also improved, but there was no associated decrease in lymphocyte infiltration. However, the expression of Fas ligand (FasL) in NOD mice by infiltrating lymphocytes was suppressed with 0.1% CyA eye drops.

CONCLUSIONS. CyA appears to improve tear secretion in mouse models of Sjögren’s syndrome by preventing lymphocyte-induced apoptosis of acinar cells. In one model this was achieved by preventing lymphocyte infiltration and in the other by reducing expression of FasL expression on infiltrating lymphocytes.




This article has been cited by other articles:


Home page
 IOVSHome page
H. Toshida, D. H. Nguyen, R. W. Beuerman, and A. Murakami
Neurologic Evaluation of Acute Lacrimomimetic Effect of Cyclosporine in an Experimental Rabbit Dry Eye Model
Invest. Ophthalmol. Vis. Sci., June 1, 2009; 50(6): 2736 - 2741.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
B M Lodde, B J Baum, P P Tak, and G Illei
Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment
Ann Rheum Dis, November 1, 2006; 65(11): 1406 - 1413.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
I. S. J. Tuominen, Y. T. Konttinen, M. H. Vesaluoma, J. A. O. Moilanen, M. Helinto, and T. M. T. Tervo
Corneal Innervation and Morphology in Primary Sjogren's Syndrome
Invest. Ophthalmol. Vis. Sci., June 1, 2003; 44(6): 2545 - 2549.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Association for Research in Vision and Ophthalmology